A computational study of the resistance of HIV-1 aspartic protease to the inhibitors ABT-538 and VX-478 and design of new analogues

被引:24
作者
Nair, AC
Miertus, S [1 ]
Tossi, A
Romeo, D
机构
[1] UNIDO, Int Ctr Sci & High Technol, I-34014 Trieste, Italy
[2] POLY Tech SCRL, I-34012 Trieste, Italy
[3] Banaras Hindu Univ, Dept Chem, Varanasi 221005, Uttar Pradesh, India
[4] Univ Trieste, Dept Biochem Biophys & Macromol Chem, I-34127 Trieste, Italy
关键词
D O I
10.1006/bbrc.1997.8008
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Recent experimental findings with HIV-1 protease (HIV-1 PR) mutants containing variations at four residues, M46I, L63P, V82T and I84V, have shown that only mutants containing the latter two exhibit cross resistance to the inhibitors ABT-538 and VX-478. The V82T and I84V modifications in fact concern residues in the active site while the other two are in the flap (M46I) and hinge (L63P) domains of the enzyme. We have modelled the M46I/L63P, V82T/I84V and M46I/L63P/ V82T/IS4V (4X) mutants of HIV-PR and computed their complexation energies with these two inhibitors, A good correlation was found between these complexation energies and the trend in published inhibition constants for these inhibitors. Reasons for the decrease in binding affinities with the two critical mutants (V82T/I84V and 4X) have also been elucidated in detail. Based on these findings, we have designed several analogues of ABT-538 and VX-478, some of which show a better calculated binding affinity towards both mutant and wild type PR. (C) 1998 Academic Press.
引用
收藏
页码:545 / 551
页数:7
相关论文
共 28 条
  • [1] STRUCTURAL BASIS OF DRUG-RESISTANCE FOR THE V82A MUTANT OF HIV-1 PROTEINASE
    BALDWIN, ET
    BHAT, TN
    LIU, BS
    PATTABIRAMAN, N
    ERICKSON, JW
    [J]. NATURE STRUCTURAL BIOLOGY, 1995, 2 (03): : 244 - 249
  • [2] BHAT TN, A76928 HIV 1 ASPARTI
  • [3] *BIOS MSI, INS, V2
  • [4] *BIOS MSI, DISC
  • [5] THE HUMAN LUMICAN GENE - ORGANIZATION, CHROMOSOMAL, LOCATION, AND EXPRESSION IN ARTICULAR-CARTILAGE
    GROVER, J
    CHEN, XN
    KORENBERG, JR
    ROUGHLEY, PJ
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 1995, 270 (37) : 21942 - 21949
  • [6] HIV POPULATION-DYNAMICS IN-VIVO - IMPLICATIONS FOR GENETIC-VARIATION, PATHOGENESIS, AND THERAPY
    COFFIN, JM
    [J]. SCIENCE, 1995, 267 (5197) : 483 - 489
  • [7] IN-VIVO EMERGENCE OF HIV-1 VARIANTS RESISTANT TO MULTIPLE PROTEASE INHIBITORS
    CONDRA, JH
    SCHLEIF, WA
    BLAHY, OM
    GABRYELSKI, LJ
    GRAHAM, DJ
    QUINTERO, JC
    RHODES, A
    ROBBINS, HL
    ROTH, E
    SHIVAPRAKASH, M
    TITUS, D
    YANG, T
    TEPPLER, H
    SQUIRES, KE
    DEUTSCH, PJ
    EMINI, EA
    [J]. NATURE, 1995, 374 (6522) : 569 - 571
  • [8] GENERATION AND CHARACTERIZATION OF A HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 (HIV-1) MUTANT RESISTANT TO AN HIV-1 PROTEASE INHIBITOR
    ELFARRASH, MA
    KURODA, MJ
    KITAZAKI, T
    MASUDA, T
    KATO, K
    HATANAKA, M
    HARADA, S
    [J]. JOURNAL OF VIROLOGY, 1994, 68 (01) : 233 - 239
  • [9] FRECER V, 1997, IN PRESS DRUG DESIGN
  • [10] KINETIC CHARACTERIZATION AND CROSS-RESISTANCE PATTERNS OF HIV-1 PROTEASE MUTANTS SELECTED UNDER DRUG PRESSURE
    GULNIK, SV
    SUVOROV, LI
    LIU, BS
    YU, B
    ANDERSON, B
    MITSUYA, H
    ERICKSON, JW
    [J]. BIOCHEMISTRY, 1995, 34 (29) : 9282 - 9287